TY - JOUR
T1 - Glucocorticoid induced TNF receptor family-related protein (GITR) – A novel driver of atherosclerosis
AU - Bosmans, Laura A.
AU - Shami, Annelie
AU - Atzler, Dorothee
AU - Weber, Christian
AU - Gonçalves, Isabel
AU - Lutgens, Esther
N1 - Funding Information:
This work was supported by the following grants: We acknowledge the support from the Netherlands CardioVascular Research Initiative : the Dutch Heart Foundation , Dutch Federation of University Medical Centres , the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences for the GENIUS-II project “Generating the best evidence-based pharmaceutical targets for atherosclerosis” [ CVON2017-20 to E.L.,.], the Deutsche Forschungsgemeinschaft [ CRC 1123 to D.A., E.L., C.W.]; the Netherlands Organization for Scientific Research (NWO) [VICI grant to E.L.]; the European Research Council (ERC consolidator grant to E.L, ERC advanced grant to C.W.) , the Swedish Research Council (to I.G.) , the Swedish Heart and Lung Foundation (to I.G., A.S.) , the SUS Foundation (to I.G.) and Swedish Foundation for Strategic Research Dnr IRC15-0067 (to I.G.).
Publisher Copyright:
© 2021
PY - 2021/8
Y1 - 2021/8
N2 - Atherosclerosis is a lipid-driven, chronic inflammatory disease. In spite of efficient lipid lowering treatments, such as statins and PCSK9 inhibitors, patients, especially those with elevated inflammatory biomarkers, still have a significant residual cardiovascular disease risk. Novel drugs targeting inflammatory mediators are needed to further reduce this residual risk. Agonistic immune checkpoint proteins, including CD86, CD40L and CD40, have been shown to be drivers of atherosclerosis. Recently, glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR), a co-stimulatory immune checkpoint protein, was identified to be pivotal in cardiovascular disease. Cardiovascular patients have elevated soluble GITR plasma levels compared to healthy controls. Furthermore, in human carotid endarterectomy plaques, GITR expression was higher in plaques from symptomatic compared to asymptomatic patients and correlated with features of plaque vulnerability. Moreover, depleting GITR reduced atherosclerotic plaque development in mice. GITR-deficient monocytes and macrophages exhibited less inflammatory potential and reduced migratory capacity. In this review, we discuss GITR's effects on various immune cells, mechanisms, signalling pathways and finally GITR's potential as a novel drug target in atherosclerosis.
AB - Atherosclerosis is a lipid-driven, chronic inflammatory disease. In spite of efficient lipid lowering treatments, such as statins and PCSK9 inhibitors, patients, especially those with elevated inflammatory biomarkers, still have a significant residual cardiovascular disease risk. Novel drugs targeting inflammatory mediators are needed to further reduce this residual risk. Agonistic immune checkpoint proteins, including CD86, CD40L and CD40, have been shown to be drivers of atherosclerosis. Recently, glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR), a co-stimulatory immune checkpoint protein, was identified to be pivotal in cardiovascular disease. Cardiovascular patients have elevated soluble GITR plasma levels compared to healthy controls. Furthermore, in human carotid endarterectomy plaques, GITR expression was higher in plaques from symptomatic compared to asymptomatic patients and correlated with features of plaque vulnerability. Moreover, depleting GITR reduced atherosclerotic plaque development in mice. GITR-deficient monocytes and macrophages exhibited less inflammatory potential and reduced migratory capacity. In this review, we discuss GITR's effects on various immune cells, mechanisms, signalling pathways and finally GITR's potential as a novel drug target in atherosclerosis.
KW - Atherosclerosis
KW - CVD
KW - Costimulatory molecule
KW - GITR
KW - Immune checkpoint
UR - http://www.scopus.com/inward/record.url?scp=85107755710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107755710&partnerID=8YFLogxK
U2 - 10.1016/j.vph.2021.106884
DO - 10.1016/j.vph.2021.106884
M3 - Review article
C2 - 34102305
AN - SCOPUS:85107755710
VL - 139
JO - Vascular Pharmacology
JF - Vascular Pharmacology
SN - 1537-1891
M1 - 106884
ER -